Basic Information
| RNALocate ID: | RLID:11003984 |
| RNA Symbol: | hsa-miR-500a-5p |
| Localization: | Microvesicle |
RNA Information
| RNA Name: | hsa-miR-500 |
| RNA ID: | miRBase:MIMAT0004773 |
| RNA Category: | miRNA |
| Species: | Homo sapiens |
Localization Information
| PubMed ID: | 23539611 |
| Tissue/Cell Line: | Seminal plasma |
| Method: | Microarray |
| Description: | In order to assess the reversibility of post-vasectomy miRNA sequelae, we investigated whether SMV miRNAs altered by vasectomy could be retrieved in SMVs from normospermic vasovasostomized donors. miRNA microarray profiling performed on SMVs from normal, vasectomized and vasovasostomized donors identified 313 miRNAs whose intensity was above the threshold of detection. Among these miRNAs, 293 were detected in samples from normal donors, 275 in vasectomized donors and 298 in vasovasostomized donors (Fig. 3, Supplementary data, Table SIV). Data are collected from Table S4. |
Other Subcellular Localization
| RNALocate ID | Localization | Tissue/Cell line | PubMed ID |
| RLID:01002664 | Mitochondrion | Skeletal muscle myoblasts | 21637849 |
| RLID:01002665 | Nucleus | Breast adenocarcinoma cells (MCF-7)|Cervical adenocarcinoma cells (HeLa) | 24918059 |
| RLID:11003982 | Exosome | Primary dendritic cells | 21505438 |
| RLID:11003983 | Exosome | Plasma | 23663360 |
| RLID-D:11000685 | Microvesicle | Colon cancer cell line (LIM1863)|Fibroblasts|Mesenchymal stem cells | |
| RLID-D:11001555 | Exosome | Breast milk|Cell lines|Epididymal epithelial cells|Osteoblast|Plasma|Primary glioblastoma neurosphere cells|Primary keratinocyte|Saliva|Serum|Urine |
ncRNA Disease Information
| Resource | RNA Symbol | Disease | Link |
| MNDR | hsa-miR-500a-5p | Medulloblastoma | MNDR-E-MI-55312 |
| MNDR | hsa-miR-500a-5p | High-grade serous ovarian carcinoma | MNDR-E-MI-55313 |
| MNDR | hsa-miR-500a-5p | Ovarian clear cell carcinoma | MNDR-E-MI-55314 |
| MNDR | hsa-miR-500a-5p | Uterine corpus endometrial carcinoma | MNDR-E-MI-55315 |
| MNDR | hsa-miR-500a-5p | Estrogen-receptor positive breast cancer | MNDR-E-MI-55316 |
| MNDR | hsa-miR-500a-5p | Progesterone-receptor positive breast cancer | MNDR-E-MI-55317 |
| MNDR | hsa-miR-500a-5p | Progesterone-receptor negative breast cancer | MNDR-E-MI-55318 |
| MNDR | hsa-miR-500a-5p | Her2-receptor positive breast cancer | MNDR-E-MI-55319 |
| MNDR | hsa-miR-500a-5p | Lupus nephritis | MNDR-E-MI-55320 |
| MNDR | hsa-miR-500a-5p | Prostate cancer | MNDR-E-MI-55321 |
| MNDR | hsa-miR-500a-5p | Gastric cancer | MNDR-E-MI-55322 |
| MNDR | hsa-miR-500a-5p | Alzheimer disease | MNDR-E-MI-55323 |
| MNDR | hsa-miR-500a-5p | Dysautonomia familial | MNDR-E-MI-55324 |
| MNDR | hsa-miR-500a-5p | Seizures | MNDR-E-MI-55325 |
| MNDR | hsa-miR-500a-5p | Leukemia | MNDR-E-MI-55326 |
| MNDR | hsa-miR-500a-5p | Friedreich ataxia | MNDR-E-MI-55327 |
| MNDR | hsa-miR-500a-5p | Lung cancer | MNDR-E-MI-55328 |
| MNDR | hsa-miR-500a-5p | Down syndrome | MNDR-E-MI-55329 |
| MNDR | hsa-miR-500a-5p | Parkinson disease | MNDR-E-MI-55330 |
| MNDR | hsa-miR-500a-5p | Breast cancer | MNDR-E-MI-55331 |
| MNDR | hsa-miR-500a-5p | Pancreatic cancer | MNDR-E-MI-55332 |
| MNDR | hsa-miR-500a-5p | Melanoma | MNDR-E-MI-55333 |
| MNDR | hsa-miR-500a-5p | Nephroblastoma | MNDR-E-MI-55334 |
| MNDR | hsa-miR-500a-5p | Multiple sclerosis relapsing-remitting | MNDR-E-MI-55335 |
| MNDR | hsa-miR-500a-5p | Familial ovarian cancer | MNDR-E-MI-55336 |
| MNDR | hsa-miR-500a-5p | Prostate adenocarcinoma | MNDR-E-MI-55337 |
| MNDR | hsa-miR-500a-5p | Carcinoma ductal breast | MNDR-E-MI-55338 |
| MNDR | hsa-miR-500a-5p | Glioblastoma | MNDR-E-MI-55339 |
| MNDR | hsa-miR-500a-5p | Glioma | MNDR-E-MI-55340 |
| MNDR | hsa-miR-500a-5p | Amyotrophic lateral sclerosis | MNDR-E-MI-55341 |
| MNDR | hsa-miR-500a-5p | Liposarcoma | MNDR-E-MI-55342 |
| MNDR | hsa-miR-500a-5p | Gastric adenocarcinoma | MNDR-E-MI-55343 |
| MNDR | hsa-miR-500a-5p | Lung squamous cell carcinoma | MNDR-E-MI-55344 |
| MNDR | hsa-miR-500a-5p | Lung adenocarcinoma | MNDR-E-MI-55345 |
| MNDR | hsa-miR-500a-5p | Adrenocortical carcinoma | MNDR-E-MI-55346 |
| MNDR | hsa-miR-500a-5p | Ovarian carcinoma | MNDR-E-MI-55347 |
| MNDR | hsa-miR-500a-5p | Pancreatic adenocarcinoma | MNDR-E-MI-55348 |
| MNDR | hsa-miR-500a-5p | Myasthenia gravis autoimmune experimental | MNDR-E-MI-55349 |
| MNDR | hsa-miR-500a-5p | Kidney renal clear cell carcinoma | MNDR-E-MI-55350 |
| MNDR | hsa-miR-500a-5p | Kidney renal papillary cell carcinoma | MNDR-E-MI-55351 |
| MNDR | hsa-miR-500a-5p | Clear cell renal cell carcinoma | MNDR-E-MI-55352 |
| MNDR | hsa-miR-500a-5p | Cholangiocarcinoma | MNDR-E-MI-55353 |
| MNDR | hsa-miR-500a-5p | Stomach carcinoma | MNDR-E-MI-55354 |
| MNDR | hsa-miR-500a-5p | T acute lymphoblastic leukemia | MNDR-E-MI-55355 |
| MNDR | hsa-miR-500a-5p | Acute t cell leukemia | MNDR-E-MI-55356 |
| MNDR | hsa-miR-500a-5p | Breast invasive carcinoma | MNDR-E-MI-55357 |
| MNDR | hsa-miR-500a-5p | Hepatocellular carcinoma | MNDR-E-MI-55358 |
| MNDR | hsa-miR-500a-5p | Familiar ovarian carcinoma | MNDR-E-MI-55359 |
| MNDR | hsa-miR-500a-5p | Retinoblastoma | MNDR-E-MI-55360 |
| MNDR | hsa-miR-500a-5p | Tonsil cancer | MNDR-E-MI-55361 |
| MNDR | hsa-miR-500a-5p | Neuromyelitis optica | MNDR-E-MI-55362 |
| MNDR | hsa-miR-500a-5p | Colorectal cancer | MNDR-E-MI-55363 |
| MNDR | hsa-miR-500a-5p | Nasopharynx carcinoma | MNDR-E-MI-55364 |
| MNDR | hsa-miR-500a-5p | Multiple myeloma | MNDR-E-MI-55365 |
| MNDR | hsa-miR-500a-5p | Nasopharyngeal cancer | MNDR-E-MI-55366 |
| MNDR | hsa-miR-500a-5p | Gait ataxia | MNDR-E-MI-55367 |
| MNDR | hsa-miR-500a-5p | Stroke lacunar | MNDR-E-MI-55368 |
| MNDR | hsa-miR-500a-5p | Breast cancer her3+ negative | MNDR-E-MI-55369 |
RNA Interaction Information
| Resource | RNA Symbol | Species | Link | RNALocate ID |
| RNAInter | CYLD | Homo sapiens | RR00385277 |
TOP